Prior authorization denied after losing weight: what to do

Why renewals get denied after you lose weight

A prior authorization is your plan's advance approval to cover a drug. Many plans approve a GLP-1 for a set period and then require a renewal, and the renewal is judged against the plan's written criteria at that time. That is how people who are responding to treatment end up denied. The common reasons:

• Your BMI is now below the starting threshold. If the renewal is judged against the same BMI cutoff used for your first approval, the weight you have lost can put you under it.
• The plan changed its criteria. A new plan year can bring a higher BMI threshold, a required number of related health conditions, or an exclusion of weight-loss use altogether.
• Step therapy. The plan may now require you to try a different, preferred drug first.
• Missing documentation. Renewals can require records of your current weight, your response to treatment, or a lifestyle program, so a denial can come from a missing record rather than a clinical judgment.
• A formulary change. Your plan may now prefer a different GLP-1.

Start with the denial letter and the plan's criteria

The denial letter tells you what to fix. Look for three things: the specific reason for the denial, the criteria the plan applied, and the deadline and method for an appeal. If the letter doesn't spell out the criteria, call the member services number on your insurance card and ask for the written prior authorization criteria for your drug.

According to HealthCare.gov, if your health insurer refuses to pay a claim or ends your coverage, you have the right to appeal the decision and have it reviewed by a third party. If your plan comes through an employer, the HR benefits team can also tell you whether the criteria changed for the new plan year, and whether another plan option at open enrollment treats the drug differently.

Questions to ask your prescriber

Your prescriber prepares the resubmission and supports any appeal, so this conversation matters most. None of these questions guarantees approval; the plan's criteria decide. Bring the denial letter and ask:

• Can the resubmission document my starting BMI and my weight history from before treatment, and do the plan's renewal criteria allow that?
• Do I have health conditions that the plan's criteria recognize, and are they documented in my record?
• If the plan requires step therapy, does my record show which drugs I have already tried?
• Can you request a peer-to-peer review with the plan's clinical reviewer?
• If this drug stays denied, is there a medication on my plan's formulary that fits my history?
• How should we handle the time between fills while the appeal is pending?

How the appeal process works

Appeals usually run in two stages. Your denial letter and plan documents set the exact steps and deadlines for your plan, so follow those first.

Internal appeal. You, or your prescriber on your behalf, ask the plan to reconsider. Include the denial letter, a letter from your prescriber explaining why the medication is medically necessary for you, and the records that answer the stated reason for denial, such as your weight history before treatment. HealthCare.gov states that if a claim is denied, you have the right to an internal appeal. Most plans must offer both stages; Medicare and some older grandfathered plans follow different rules, and your denial letter explains yours.

External review. If the plan upholds its denial, you can take the appeal to an independent third party. As HealthCare.gov puts it, external review means "the insurance company no longer gets the final say over whether to pay a claim." Your denial notice should explain how to request it.

If you are unsure which rules apply, ask your plan's member services, or your HR benefits team for an employer plan. Your state's insurance department can also answer questions about appeals for the plans it regulates.

If the appeal does not succeed: your other options

If the plan's decision stands, check these in order.

A covered alternative. Ask your prescriber whether another drug on your plan's formulary fits your history. Your prescriber decides whether a switch makes sense and at what dose.

Manufacturer self-pay. LillyDirect sells Zepbound vials from $299 a month for 2.5 mg ($399 for 5 mg, and $449 for 7.5 mg to 15 mg on the first fill and on refills within 45 days of the previous delivery), with no published end date; KwikPens cost the same through Lilly's KwikPen self-pay program, which ends December 31, 2026. NovoCare sells Wegovy pens at $349 a month ($399 for Wegovy HD 7.2 mg), after a $199 introductory price for a new patient's first two fills of the 0.25 mg or 0.5 mg pen through December 31, 2026, and Wegovy tablets from $149 a month (1.5 mg; $199 for 4 mg, $299 for 9 mg or 25 mg). NovoCare says its pricing will be updated after December 31, 2026. Prices per LillyDirect, Lilly's Zepbound savings terms and NovoCare, checked September 24, 2026. The full price list is in our coverage-changed guide.

Medicare's GLP-1 Bridge. If you have Medicare Part D and meet the eligibility criteria, the Bridge charges a $50 copayment for a one-month supply of Wegovy injection or tablets, Foundayo, or the Zepbound KwikPen (not Zepbound vials or single-dose pens) through December 31, 2027. That is likely to cost less than any cash-pay price on this page, including Cora's plans for compounded medication, which is not FDA-approved and is not therapeutically equivalent to FDA-approved products. Your provider submits a prior authorization, and once approved it stays valid through December 31, 2027 unless the drug changes (CMS, checked September 24, 2026).

Compounded medication through a licensed provider. Some people consider compounded semaglutide or compounded tirzepatide prescribed by a licensed provider. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved products. A licensed provider decides whether compounded medication is appropriate for you. Brand-name and compounded doses are not interchangeable, and there is no dose conversion between them; your provider determines the right dose based on your history.

Where Cora fits

Cora Health does not bill insurance, so it plays no part in your prior authorization or appeal. If your appeal does not succeed and you are weighing compounded medication, Cora connects patients with licensed providers at Wasef Health, PC, who may prescribe compounded semaglutide or compounded tirzepatide when appropriate; a US-licensed 503A compounding pharmacy prepares and dispenses the medication. Cora does not prescribe or compound medication. Plans start at $99/month for compounded semaglutide and $135/month for compounded tirzepatide on the annual plan ($1,188 and $1,620 billed every 12 months). Prices may change. Each price includes the provider consultation, the medication, pharmacy fulfillment, shipping and ongoing provider monitoring, with no separate membership fee. Plans renew automatically until you cancel (see our refund policy). Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products. Every tier is on the plans page.

FAQ: prior authorization denials

Do I have to regain weight to qualify again? Don't try to. Ask your prescriber whether the plan's renewal criteria allow your weight history before treatment to be documented, and appeal if the plan applied criteria that don't fit your situation. Whether the plan accepts it is up to the plan.

Is an appeal worth it if the new criteria require a higher BMI plus other health conditions? It depends on whether your documented history meets the criteria. Ask your prescriber to compare your record against the plan's written criteria before you decide. If your record does not meet them, ask your prescriber whether a medical-necessity appeal is still worth filing. You keep the right to appeal either way, and the options above remain available if it does not succeed.

Can my prescriber try a different GLP-1 instead? Ask. If another drug is preferred on your formulary, your prescriber can decide whether it fits your history and submit a prior authorization for it. Your prescriber determines the dose based on your history.

Sources

Last verified: September 24, 2026. Appeal rights, deadlines and steps vary by plan; your denial letter and plan documents are the final word for your coverage. This article is general information, not medical, legal or insurance advice. Wegovy® and Zepbound® are registered trademarks of their respective owners; NovoCare, LillyDirect, KwikPen and Foundayo are trademarks of their respective owners. Cora Health is not affiliated with Novo Nordisk or Eli Lilly.

• HealthCare.gov: Appealing a health insurance company decision (checked September 24, 2026). healthcare.gov
• CMS: Medicare GLP-1 Bridge (checked September 24, 2026). cms.gov
• Medicare.gov: Weight-loss drug coverage (checked September 24, 2026). medicare.gov
• Eli Lilly: LillyDirect Zepbound self-pay pricing (checked September 24, 2026). lilly.com
• Novo Nordisk: NovoCare Pharmacy Wegovy pricing (checked September 24, 2026). novocare.com